AOD-9604 for Weight Loss: The Obesity Drug That Failed in Human Trials

AOD-9604 — literally “Advanced Obesity Drug 9604” — is the rare research peptide that was built specifically to treat obesity and actually made it into human trials. That is exactly why its story matters: it is the cautionary tale of the whole “fat-loss peptide” category. AOD-9604 is a synthetic fragment of the tail end (C-terminus) of human growth hormone, developed by Metabolic Pharmaceuticals in Australia. In obese mice it produced fat loss^[3][4], which fueled real hope. But when it was advanced into human obesity trials in the 2000s, it failed to deliver clinically meaningful weight loss, and the program was abandoned as a weight-loss drug. Today it has no FDA approval for any indication and is sold grey-market as a “research peptide.” This article reviews what the animal data showed, what the human trials found, the regulatory reality, and how AOD-9604 compares to FDA-approved obesity drugs that did succeed in Phase 3. This is an evidence review — not a dosing or how-to-buy guide.

The honest summary

• Built to be an obesity drug. AOD-9604 (“Advanced Obesity Drug 9604”) is a synthetic peptide copying the lipolytic C-terminal fragment of human growth hormone (hGH 176–191). It was engineered by Metabolic Pharmaceuticals specifically to burn fat without the growth-promoting, blood-sugar-raising effects of full-length growth hormone^[5].
• Animal data were positive. In obese mice, chronic AOD-9604 increased fat oxidation and reduced body weight^[3][4]. This is the “animal-positive” half of the story and the reason the compound was taken into clinical development.
• Human data were negative. The compound advanced into human obesity trials (Phase IIa underway by 2002^[6]), but the program failed to produce clinically meaningful weight loss versus placebo, and development as a weight-loss drug was discontinued. No positive human weight-loss result for AOD-9604 has ever been published or approved.
• No FDA approval for anything. AOD-9604 is not an approved drug for weight loss or any other human use. It is not listed in DailyMed, and US regulators have acted against companies marketing it for human consumption.
• Now a grey-market research chemical. It is sold online “for research use only,” with no agency verifying the identity, purity, sterility, or dose in the vial.
• Drugs that worked look different. Semaglutide and tirzepatide each cleared large Phase-3 human trials (mean weight loss of about −14.9% and −20.9%)^[1][2]. That is the bar AOD-9604 was tested against — and did not clear.

What AOD-9604 actually is

Human growth hormone (hGH) has long been known to have a fat-mobilizing (lipolytic) effect, but using whole hGH for weight loss is impractical: it also raises blood sugar, promotes tissue growth, and carries real side effects. Researchers at Monash University and the company Metabolic Pharmaceuticals reasoned that the fat-burning activity might live in just one piece of the molecule — the C-terminal tail. AOD-9604 is a synthetic peptide built around that fragment (residues 176–191 of hGH, with a small modification), designed to keep the lipolytic effect while dropping the growth-promoting and glucose-raising effects of the full hormone^[5]. The name says the goal out loud: “Advanced Obesity Drug 9604.” It was, in other words, a serious pharmaceutical anti-obesity candidate — not a bodybuilding-forum invention.

The animal evidence was genuinely promising

The preclinical case for AOD-9604 was real. In obese (ob/ob) mice, chronic treatment with AOD-9604 increased fat oxidation and produced weight loss, with the published work directly comparing the fragment to full-length growth hormone and reporting weight and energy-balance effects^[3]. A companion study examined how the fragment affects lipid metabolism after chronic treatment in obese mice and in beta-3 adrenergic-receptor knockout mice, probing the mechanism of its lipolytic action^[4]. Earlier mechanistic work characterized the synthetic lipolytic domain itself and its metabolic activity^[5]. Taken together, this is a coherent, encouraging animal package: a designed fragment that appeared to do exactly what it was built to do in rodents.

The human obesity trials — where it actually failed

This is the crux, and what sets AOD-9604 apart from most “fat-loss peptides”: it was actually tested in people. Metabolic Pharmaceuticals advanced AOD-9604 into a human obesity development program, with Phase IIa trials underway by early 2002^[6]. The trials enrolled adults with obesity and tested AOD-9604 over a course of weeks against placebo. The program did not produce the clinically meaningful, statistically convincing weight loss needed to support an obesity drug, and development of AOD-9604 as a weight-loss therapeutic was discontinued. No positive human weight-loss result for AOD-9604 has ever been published in the peer-reviewed literature, and no regulator has approved it for obesity anywhere.

It is worth being precise about the evidence trail here, because YMYL health claims demand it. A PubMed search for AOD-9604 returns its animal and mechanistic studies, doping-control detection assays, and development reviews — but no standalone human results paper reporting that it caused weight loss. The clinical-development review that documents the program reaching Phase IIa is the published anchor^[6]; the negative outcome is reflected in the simple fact that the compound was never published as a successful obesity drug and never approved. In short: the positive evidence is in mice, and the human program did not replicate it. “Worked in mice, tested in humans, did not work” is the most honest one-line summary of AOD-9604.

Regulatory reality: not approved, now grey-market

AOD-9604 has no FDA approval for weight loss or for any other human indication, and it is not listed as an approved drug in DailyMed. After the obesity-drug program lapsed, the compound was pursued through other channels — including attempts to position it as a food/dietary ingredient — but a food-ingredient or “generally recognized” status is not a finding that it causes weight loss, and it is not an approved weight-loss treatment. In practice, AOD-9604 today is sold online as a “research peptide,” typically labeled “for research use only — not for human consumption.” US regulators have taken enforcement steps against companies distributing unapproved peptides, including AOD-9604, for human use. When you buy it, no agency has verified what is in the vial.

What an evidence-backed weight-loss drug looks like

The contrast with FDA-approved obesity medications is the whole point. AOD-9604 reached Phase 2 and stalled. Semaglutide (Wegovy) went the full distance: in the STEP-1 Phase-3 randomized, double-blind, placebo-controlled trial, adults with overweight or obesity lost a mean of about −14.9% of body weight at 68 weeks versus −2.4% on placebo^[1]. Tirzepatide (Zepbound) in the SURMOUNT-1 trial reached a mean reduction of up to −20.9% at 72 weeks^[2]. Both are large, pre-registered human randomized controlled trials with thousands of participants, published in the New England Journal of Medicine, supporting an FDA-approved indication. That is what “works for weight loss” looks like in the evidence — and it is precisely what AOD-9604 was tested for and did not achieve.

For the wider map of this landscape, see our hub review of peptides for weight loss, which sorts FDA-approved peptide drugs from compounded versions and unapproved research peptides, and the companion review of non-GLP-1 peptides marketed for fat loss, which ranks AOD-9604 alongside tesofensine and cagrilintide by evidence quality. For another “animal-only” research peptide with no human weight-loss trial, see our review of BPC-157 for weight loss.

Bottom line

AOD-9604 is the most instructive peptide in the whole “fat-loss” conversation precisely because it was given a fair shot. It was designed to be an obesity drug, it had genuinely promising obese-mouse data^[3][4], it had a real pharmaceutical developer, and it was tested in human obesity trials^[6] — and it still failed to deliver weight loss and was abandoned. It has no FDA approval, no positive published human result, and is now sold as an unregulated research chemical whose contents are unverified. If a peptide that was purpose-built for obesity and taken into human trials could not clear the bar, that should reset expectations for every other “research peptide” sold for fat loss. If your goal is weight loss, the evidence points to FDA-approved medications with successful human trials^[1][2] — not to AOD-9604.

This article is educational and is not medical advice. Every claim above is sourced to peer-reviewed literature indexed in PubMed or to the regulatory status of the compound, verified against the live PubMed database before publication. Citations 3 through 5 are animal (mouse) or mechanistic studies of AOD-9604; citation 6 is a clinical-development review documenting the human obesity program; citations 1 and 2 are human Phase-3 randomized controlled trials of FDA-approved drugs cited for contrast. Discuss any weight-loss treatment with a licensed prescriber.